BUY Mankind Pharma Limited — Pankaj Randad
byPankaj RandadHorizon: NA (inferred Swing (≤2wk))4 Jun 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·3 Jun · 5d ago
Mankind Pharma Limited, through its subsidiary, acquired the remaining 10% stake in Upakarma Ayurveda Private Limited, making Upakarma a wholly-owned subsidiary. This acquisition aims to improve opera
NSE · Acquisition·2 Jun · 6d ago
Mankind Pharma Ltd has informed about a stake acquisition by one of its wholly-owned subsidiary companies.
BSE · Company Update·2 Jun · 6d ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Mankind Pharma
- BUY — Rajesh Satpute7 Oct 2026 · Next day · target ₹2,550 · SL hit
- BUY — Swati Hotkar, Nirmal Bang Securities7 Oct 2026 · Same day · target ₹2,580 · Expired
- SELL — Macquarie7 Oct 2026 · ~1 year · target ₹2,200 · Target hit
- BUY — Vishvesh Chauhan, ChaseAlpha30 Sept 2026 · ~2 weeks · target ₹2,640 · SL hit
- BUY — Raja Venkatraman30 Sept 2026 · ~3 months · target ₹2,800 · SL hit
More from Pankaj Randad
- SELL Jubilant FoodWorks23 Oct 2026 · ~3 months · target ₹380 · Active
- BUY ICICI Prudential Life Insurance Company23 Oct 2026 · ~1 year · target ₹480 · Active
- BUY HBL Engineering16 Oct 2026 · ~2 weeks · target ₹820 · Target hit
- BUY Suven Life Sciences15 Oct 2026 · ~2 weeks · target ₹330 · SL hit
- BUY JK Paper14 Oct 2026 · ~2 weeks · target ₹430 · SL hit